Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage oncology company developing antibody-drug conjugates for difficult-to-treat solid tumors, with an immediate focus on recurrent and metastatic head and neck squamous cell carcinoma. Its lead investigational candidate, micvotabart pelidotin (MICVO), targets… From the company’s description.
In fiscal 2025, Pyxis Oncology, Inc. reported revenue of $13.86M, down 14.2% from fiscal 2024, and a net loss of $79.62M. Its operating margin was −609.2%, and operations used $63.50M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pyxis Oncology, Inc. does
In the company’s own words
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage oncology company developing antibody-drug conjugates for difficult-to-treat solid tumors, with an immediate focus on recurrent and metastatic head and neck squamous cell carcinoma. Its lead investigational candidate, micvotabart pelidotin (MICVO), targets extradomain-B fibronectin in the tumor extracellular matrix and is being studied as a monotherapy and in combination with pembrolizumab. The company’s clinical program also evaluates MICVO across other advanced solid tumors, including breast, lung, ovarian, pancreatic and cervical cancers. Pyxis was founded in 2018 and began operations in 2019; it uses the Flexible Antibody Conjugation Technology platform for ADC development and the APXiMAB platform for antibody discovery and development. It conducts clinical development through Phase 1 and Phase 1/2 studies, including a collaboration with Merck for the pembrolizumab combination study. Pyxis Oncology has no reportable business segments described here. Its website is https://pyxisoncology.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1782223
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pyxis Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pyxis Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pyxis Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pyxis Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pyxis Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”